The measurement of serum and amniotic-fluid alphafetoprotein (AFP) concentration along with an electrophoretic acetylcholinesterase screen of the amniotic fluid has become widely used to identify pregnancies at-risk of being associated with (open) neural-tube defects (NTD). 2 The interpretation of such risks is complicated by a marked overlap between the AFP concentration observed in nonaffected pregnancies and those in NTD-affected pregnancies, as shown in Fig. 1 . The overlap is more marked in maternal serum than in amniotic-fluid.
There is no clear transition from zero risk to absolute certainty of an affected pregnancy. Cut-off levels have been establighed for population screening purposes,'2 these being designed to minimise the number of misclassifications-that is, they represent an optimal compromise between the number of healthy pregnancies subjected to unnecessary (and risk-associated) follow-up procedures, and those affected pregnancies that remain undetected in the screening programme. Mothers with serum AFP concentrations equal to, or greater than the established serum cut-off value represent a specific subpopulation for whom the risk of an NTDassociated fetus is sufficiently great to justify the risks inherent in performing an amniocentesis. Amniotic fluid AFP concentrations equal to or greater than the appropriate amniotic-fluid cut-off level define a "high-risk" subpopulation. The screening risks Accepted for publication 7 Neural-tube defect risk assessment for individual pregnancies Screening risk assessments are of value in planning an efficient screening service. They have no bearing upon the interpretation of risks for an individual pregnancy. This point has been made before.34 The procedure for evaluating individual risks, based on continuous test variables, is well established' but the exact arithmetical steps involved are not widely known. The unfortunate consequences that will follow from a blanket application of screening probabilities (risks) to individual pregnancies associated with borderline rises in AFP (in serum and amniotic fluid), have prompted this communication.
Material and methods
The information required to perform an individual risk assessment falls into two categories: personal data and population data.
PERSONAL DATA (a) The patient's estimated serum and amniotic fluid AFP values, along with the result of an acetylcholinesterase screening test are required. It is assumed that the amniotic fluid AFP result has been corrected for the effects of fetal blood contamination (should this be present). A provisional correction procedure has been described.2 The AFP measurements are subject to a marked interlaboratory variation, in recognition of which a reporting system based on multiples of locally established reference population medians (MoM) has been adopted. 2 (b) An estimate of the gestational age is required, preferably supported by evidence from ultrasound scanning. Any history of previous NTD affected pregnancies in the subject mother should be noted. We assume that the imprecision of the AFP assay method used in the screening programme is similar to that used in establishing the population data of(a) above. Under this assumption, no account need be taken of the assay imprecision in the risk assessment procedure since this source of error is already incorporated in the distributional data itself.
(c) The proportion of NTD affected pregnancies giving positive acetylcholinesterase test results (true positives) and the proportion of non-NTD affected pregnancies giving positive acetylcholinesterase results (false-positives) are required for the subpopulation of mothers with (serum and) amniotic fluid AFP values in excess of the established "at-risk" cut-off values. The values used in this report have been abstracted from the report of the UK Collaborative Acetylcholinesterase study.7 A distinction is made between the proportions observed for fetally bloodstained amniotic fluid samples and those observed for maternally bloodstained or clear samples.
CALCULATION OF INDIVIDUAL RISKS
The risk assessment procedure is a straightforward application of Bayes' theorem for continuous variables,8 the exact arithmetical steps involved being described in Appendix I. A computer implementation of the procedure (using a WANG 2200-MVP system, Wang Laboratories Inc, Lowell, Mass, USA) has been used to generate a graphical substitute for the arithmetical calculations to permit immediate access to individual risk assessments. The graphs are presented in Figs. 2-4. The are specifically restricted to the assessment of singleton pregnancies with no previous history of NTD affected infants given an NTD prevalence of 4 per 1000 births in the population under study. Figure 2 provides a preliminary NTD risk given both serum and amniotic fluid AFP specimens drawn in the 16-18 wk gestation period. Figure 3 is appropriate when the serum AFP specimen is drawn at 16-18 wk gestation with the amniotic fluid AFP specimen drawn at 19-21 wk gestation. Any pregnancies not covered by these assumptions can be assessed independently using the full calculation procedures of Appendix I.
The use of these graphs is best described by example. Given a serum AFP concentration of 3 0 MoM (at 16-18 wk) and an amniotic fluid AFP of [3] [4] [5] [6] MoM (also at 16-18 wk) we refer to Fig. 2 The use of probabilities in assessing individual cases demands a certain degree of common sense. In absolute terms the mother is either carrying an NTD affected fetus, or she is not. There is no uncertainty about that. The uncertainty lies in our perception of the true state of affairs obtaining for any given pregnancy. The procedures described are an efficient means of representing those uncertainties.
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Appendix I Calculation procedure STAGE I To illustrate the calculation procedure we will adopt a serum AFP value of 3 MoM at a gestational age of 16 wk, the pregnancy being singleton with no previous history of NTD affected infants. The prevalence of NTD is taken as being 4 Calculate the normal density f(Z) for each state using Appendix II. We will refer to these densities as "likelihoods. For Fig. 4 , the overall NTD risks are given as the sum of the spina bifida and anencephaly probabilities.
Appendix II Standard normal densities
We require the normal density f(Zi) for any given standard normal deviate Z1. Tables of the standard normal integral (as opposed to density) tabulate areas under the curve-for example the area under the curve to the right of Z1 in Fig. 1 . These would be appropriate to the computation of screening risk assessments where interest is focused on the risk associated with test values equal to or greater than a specified cut-off level Z1. 
